Natera Inc. Stock Price Experiences Moderate Increase
Natera Inc., a biotechnology company specializing in diagnostic services, has seen its stock price increase in recent days. The company’s stock price movement is attributed to its focus on preconception and prenatal genetic testing, as well as pre-implantation genetic diagnosis.
Analyst Recognition
Evercore ISI has initiated a positive rating for Natera Inc. and set a price target, recognizing the company’s expertise in genetic testing. This recognition is a result of the company’s established presence in the market.
Industry Involvement
Natera Inc. has been featured in a recent report on the non-invasive prenatal testing market, alongside other industry leaders. The company’s involvement in this market highlights its commitment to innovation and advancement in diagnostic services.
Prospects and Future Applications
The company’s prospects appear promising, with potential applications in the field of kidney transplantation also on the horizon. This development suggests that Natera Inc. is poised for continued growth and expansion in the diagnostic services market.
Key Developments
- Evercore ISI initiates positive rating and sets price target for Natera Inc.
- Natera Inc. featured in recent report on non-invasive prenatal testing market
- Potential applications in kidney transplantation on the horizon